缺血修饰蛋白在急性冠状动脉综合征中的临床应用

Clinical Application of Ischemia Modified Protein in Acute Coronary Syndrome

冠心病急性心肌梗死已成为威胁人类健康的"第一号杀手",目前临床主要根据心电图和心肌坏死标志物来确诊,由于心电图的确诊率不足50%,而心肌坏死标志物肌钙蛋白在心肌坏死后3～4 h才能测出,所以不能帮助临床医师在第一时间挽救心肌。多方面研究证明缺血修饰蛋白可敏感地反映心肌缺血状况,在急性冠状动脉综合征的早期诊断、危险分层、指导治疗等方面有重要意义,是目前较为理想的检测心肌缺血的生化标志物,是第一个被美国食品药品管理局批准销售的心肌缺血标志物。现就近年来缺血修饰蛋白的发现、检测、临床应用及其局限性方面的研究予以综述。

Acute myocardial infarction coronary heart disease has become the ＂no.1 killer＂ to human health,which currently is mainly diagnosed by electrocardiogram and markers of myocardial necrosis,however,since the positive rate of electrocardiogram is less than 50%,and the markers troponin can only be tested 3 ~4 h after myocardial necrosis,they can′t help clinicians in first time to save the heart muscle.How to quickly and accurately rule out acute coronary syndrome（ACS）.Many studies have shown that ischemia modified protein can sensitively reflect myocardial ischemia status,thus is of great significance in the early diagnosis and risk stratification,and treatment guidance of ACS,an ideal myocardial ischemia biochemical marker,the first myocardial ischemia marker approved for sale by the US FDA.Here is to make a review on the discovery,detection,clinical application and its limitations of the ischemia modified protein.